ArticleNature medicine2025
Molecular determinants of sotorasib clinical efficacy in KRAS
Registry-linked trialAbstract read
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04303780 (A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C), which is not on this map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Who cites it
27 citing papers in PubMed.
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine.International journal of molecular sciences · 2026Review
- Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies.Translational lung cancer research · 2026Review
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences · 2026Review
- RAS signaling at the crossroads of radioresistance and tumor immunity.Journal for immunotherapy of cancer · 2026Review
- Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach.Neoplasia (New York, N.Y.) · 2026Review
- Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Lung Adenocarcinoma Developing Pleomorphic Carcinoma WithJTO clinical and research reports · 2026Article
- Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib.The journal of liquid biopsy · 2026Article
- Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRASScientific reports · 2026Article
- The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.Cancer research · 2026Article
- Chemotherapy in combination with KRAS inhibitors inJournal of thoracic disease · 2026Article
- Review
- MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research · 2026Article
- Context defines precision: rethinking KRAS inhibition in oncology.NPJ precision oncology · 2026Review
- Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.Cancer research communications · 2026Article
- Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.Journal for immunotherapy of cancer · 2026Article
- Targeted protein degradation dismantles undruggable targets to reverse immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
- Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer.Drug delivery and translational research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Ferdinandos SkoulidisUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA. fskoulidis@mdanderson.org.ORCID http://orcid.org/0000-0002-4676-4503
Bob T LiMemorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Adrianus Johannes de LangenNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-7343-633X
David S HongUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8721-1609
Herve LenaCentre Hospitalier Universitaire de Rennes-Hôpital Pontchaillou, Rennes, France.
Juergen WolfCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Grace K DyRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Alessandra Curioni FontecedroFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.ORCID http://orcid.org/0000-0002-5778-5270
Pascale TomasiniAix Marseille University, APHM, INSERM, NCRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France.
Vamsidhar VelchetiPerlmutter Cancer Center, New York University Langone, New York, NY, USA.
Anthonie J van der WekkenDepartment of Pulmonology and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-7175-0026
Christophe DoomsDepartment of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium.
Luis Paz-Ares RodriguezDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.ORCID http://orcid.org/0000-0002-1947-3364
Giannis MountziosFourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
Adrian SacherPrincess Margaret Cancer Centre, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7865-2701
Ernest NadalCatalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9674-5554
Sebastien CouraudCancer Institute of Hospices Civils de Lyon, Lyon Sud Hospital, Pierre Bénite, France.
Sang-We KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kenneth O'ByrnePrincess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia.
Danilo RoccoDepartment of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy.
Ryo ToyozawaDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Izabela ChmielewskaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.ORCID http://orcid.org/0000-0002-0948-9071
Colin R LindsayThe Christie NHS Foundation Trust, Manchester, UK.
Antreas HindoyanAmgen, Inc., Thousand Oaks, CA, USA.
Lata MukundanAmgen, Inc., Thousand Oaks, CA, USA.
Tomasz WilmanskiAmgen, Inc., Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0003-1059-073X
Abraham AndersonAmgen, Inc., Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0002-1624-622X
Christine Ardito-AbrahamAmgen, Inc., Thousand Oaks, CA, USA.
Amrita PatiAmgen, Inc., Thousand Oaks, CA, USA.
Anita ReddyAmgen, Inc., Thousand Oaks, CA, USA.
Bhakti MehtaAmgen, Inc., Thousand Oaks, CA, USA.
Martin SchulerDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. martin.schuler@ume.de.ORCID http://orcid.org/0000-0002-2166-3394
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Molecular determinants of KRAS(G12C)inhibitor efficacy in KRAS
Indexed as
Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationPiperazinesProto-Oncogene Proteins p21(ras)PyrimidinesDNA-Binding ProteinsDocetaxelFemaleHumansKelch-Like ECH-Associated Protein 1MaleNF-E2-Related Factor 2Precision MedicinePrognosisAntineoplastic AgentsDNA-Binding ProteinsDocetaxelKEAP1 protein, humanKelch-Like ECH-Associated Protein 1KRAS protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2PiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasibTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04303780ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.